Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Graves Disease, Graves Ophthalmopathy. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Relationship Between Systemic Inflammation, Thyroid Autoimmunity, and Neuroretinal Structures in Graves Disease
Overview
This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.
Primary outcome measures
- Peripapillary Retinal Nerve Fiber Layer Thickness [Time frame: Retrospective evaluation of OCT measurements obtained between August 2018 and January 2026]
- Macular Thickness Measured by Optical Coherence Tomography [Time frame: Retrospective evaluation of OCT measurements obtained between August 2018 and January 2026]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years
Diagnosis of Graves' disease (for the patient group)
No known thyroid disease in healthy control participants
Availability of optical coherence tomography (OCT) measurements and laboratory data
Time interval between OCT examination and blood sampling ≤ 10 days
Exclusion criteria
- Presence of glaucoma, optic neuropathy, or retinal vascular diseases
Macular diseases, uveitis, or severe refractive error (high myopia >6 diopters)
Diabetic retinopathy
History of previous intraocular surgery
History of active infection, malignancy, or systemic inflammatory disease
Poor-quality OCT measurements (segmentation errors or low signal strength)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Turkey (Türkiye) · 1 center
- Fethi Sekin City Hospital — Elâzığ
Identifiers
NCT: NCT07480720 · FSCH-2026-24-07